- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05354843
SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors
April 24, 2022 updated by: Etern BioPharma (Shanghai) Co., Ltd
A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors
This is a Phase I, open-label, multi-center, dose-finding study to assess the safety, pharmacokinetics, and preliminary efficacy of ET0038 in patients with advanced solid tumors.
It is anticipated that approximately 37 subjects will be enrolled in the dose-escalation phase of the study.
ET0038 will be administered orally once daily (QD) in 21-day treatment cycles.
Study Overview
Detailed Description
This is an open-label, multicenter, Phase 1 study of oral ET0038 monotherapy in participants with advanced solid tumors.
The study will include 2 components: 1) a Dose-Escalation Component for participants with advanced solid tumors and 2) a Dose-Expansion Component for participants with advanced solid tumors harboring certain specific mutations/rearrangements that result in hyperactivation of the RAS-MAPK pathway.
Participants will be treated until disease progression per RECIST v1.1, unacceptable toxicity, or other criteria for withdrawal are met, whichever occurs first.
Study Type
Interventional
Enrollment (Anticipated)
37
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Etern BioPharma (Shanghai) Co., Ltd
- Phone Number: 86 021 50186958
- Email: jianhua.yi@eternbio.com
Study Locations
-
-
Hunan
-
Changsha, Hunan, China, 410031
- Recruiting
- Hunan Cancer Hospital
-
Contact:
- Xia Wang
- Phone Number: 186 7026 4387
- Email: xia.wang@linkstart.com.cn
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Recruiting
- West China School of Medicine/West China Hospital of Sichuan University
-
Contact:
- Lizhu Zou
- Phone Number: 18708119607
- Email: 2920056032@qq.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses.
- Aged at least 18 years at the time of ICF signature.
- Histological or cytological confirmation of a solid tumor and have progressed despite standard therapy(ies), or are intolerant to standard therapy (ies), or have a tumor for which no standard therapy(ies) exists. Locally recurrent disease must not be amenable to surgical resection or radiotherapy with curative intent (patients who are considered suitable for surgical or ablative techniques following down-staging with study treatment are not eligible).
- Estimated life expectancy of minimum of 12 weeks.
- Patient with solid tumors must have at least 1 lesion, not previously irradiated, that can be accurately measured at pre-dose as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) with Computerised Tomography (CT) or magnetic resonance imaging (MRI) and which is suitable for accurate repeated measurements.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at ICF signature.
- Males and Females of child-bearing potential must agree to use effective contraception from the time ICF signature until 12 weeks after the last dose. Females of childbearing potential include those who are premenopausal and those who are 2 years postmenopausal. Pregnancy tests for female of child-bearing potential must have a negative serum pregnancy test at Screening.
Exclusion Criteria:
- Central nervous system metastatic disease, leptomeningeal disease, or metastatic cord compression.
- As judged by the investigator, any evidence of significant ophthalmological abnormalities including but not limited to history or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO, retinal macular degeneration, uncontrolled glaucoma, cataract or marked decrease in visual acuity, symptomatic severe dry eye, conjunctivitis, or corneal ulcer.
- Prior bone marrow or organ transplantation
- Prior treatment with ET0038 or a SHP2 inhibitor.
- Prior therapy with any investigational drugs or systemic anticancer treatment within 28 days (or a period of 5 'half-lives' of this investigational drugs or systemic anticancer treatment, whichever is the most appropriate and as judged by the investigator) at the time of ICF signature.
- Radiotherapy with a wide field of radiation within 28 days, or radiotherapy with a limited field of radiation for palliation within 14 days at the time of ICF signature, or planning radical radiation therapy while participating in the study.
- Prior major surgery (excluding placement of vascular access) within 28 days at the time of ICF signature, or planning for major surgery while participating in the study.
- With the exception of alopecia, any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE5.0) Grade 1 at the time of ICF signature.
- Any uncontrolled active infection requiring parenteral administration of antibiotics, antivirals, or antifungals at the time of ICF signature and/or within one week of Cycle 1 Day 1 (C1D1).
- Patient with a history of active pulmonary tuberculosis infection within 1 year prior to screening (as judged by investigator, active pulmonary tuberculosis infection more than 1 year and no evidence of active pulmonary tuberculosis at present will be considering eligible)
- Patient with history or presence of interstitial lung disease or interstitial pneumonitis.
- An active, or previously, autoimmune disease that may recur (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease,autoimmune thyroid disease, vasculitis, and psoriasis etc.) or high risk to such diseases.
- Active infection including hepatitis B (Hepatitis B surface antigen [HBsAg] positive), and/or hepatitis C (HCV-RNA positive).
- Active human immunodeficiency virus (HIV) infection (Patient with HIV positive and have well-controlled disease is exception).
- Patient inability or unwillingness to comply with requirement for oral drug administration or presence of a gastro-intestinal condition, e.g., Refractory nausea and vomiting, inability to swallow the formulated product or previous significant bowel resection.
- Have a history or present active bleeding disease within 6 months at the time of ICF signature.
- History of COVID-19 infections, or COVID-19 nucleic acid test positive at the time of ICF signature and/or prior to the first dose of study treatment.
- Pregnant or Breast-feeding women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Dose Escalation and Dose Expansion
ET0038 will be administered orally once daily in 21 days treatment cycles.
|
ET0038 for oral administration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
RP2D of Phase 2 Dose of ET0038
Time Frame: Approximately 2 years
|
Find RP2D
|
Approximately 2 years
|
MTD of ET0038
Time Frame: Approximately 2 years
|
Fin MTD
|
Approximately 2 years
|
Number of participants with adverse events (AEs)
Time Frame: Approximately 2 years
|
All patients participating in this study will be assessed for incidence and severity of adverse events (AEs) and serious AEs, including changes in laboratory values, vital signs, electrocardiograms, cardiac imaging and ophthalmological assessments
|
Approximately 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of response
Time Frame: Approximately 2 years
|
DOR is defined as the time from the participant's initial objective response (CR or PR) to study drug therapy, to disease progression or death due to any cause, whichever occurs first.
|
Approximately 2 years
|
Disease Control Rate
Time Frame: Approximately 2 years
|
DCR is defined as the percentage of patients who achieved remission (PR+CR) and stabilization (SD) after treatment in evaluable cases.
|
Approximately 2 years
|
Objective response rate
Time Frame: Approximately 2 years
|
ORR is defined as the proportion of participants with complete response or partial response (CR+PR)
|
Approximately 2 years
|
Area under the curve
Time Frame: Approximately 2 years
|
Area under the plasma concentration time curve of ET0038
|
Approximately 2 years
|
Cmax
Time Frame: Approximately 2 years
|
Highest observed plasma concentration of ET0038
|
Approximately 2 years
|
Tmax
Time Frame: Approximately 2 years
|
Time of highest observed plasma concentration of ET0038
|
Approximately 2 years
|
T1/2
Time Frame: Approximately 2 years
|
Half life of ET0038
|
Approximately 2 years
|
progression-free survival
Time Frame: Approximately 2 years
|
PFS is defined as the time between the onset of randomization and the onset (of any aspect) of tumor progression or death (from any cause).
|
Approximately 2 years
|
overall survival
Time Frame: Approximately 2 years
|
OS is defined as the time between the beginning of randomization and the death of the patient from any cause
|
Approximately 2 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pERK
Time Frame: Approximately 2 years
|
On treatment versus baseline comparison of pharmacodynamic marker pERK (Phosphorylated form of Extracellular signal-regulated kinase) on newly obtained tumor biopsy samples by IHC.
|
Approximately 2 years
|
NGS test of RTK/MAPK pathway genes
Time Frame: Approximately 2 years
|
Next-generation sequencing (NGS) test will be performed with the tumor tissues or plasma ctDNA collected before ET0038 treatment, to detect gene alterations within the RTK/MAPK pathway.
Detected gene alteration data (including but not limited to mutation, insertion, deletion, amplification, translocation…) will be further analyzed for correlation with the anti-tumor activity of ET0038.
|
Approximately 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Etern BioPharma (Shanghai) Co., Ltd, Etern BioPharma (Shanghai) Co., Ltd
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 27, 2021
Primary Completion (ANTICIPATED)
October 1, 2023
Study Completion (ANTICIPATED)
October 1, 2025
Study Registration Dates
First Submitted
March 17, 2022
First Submitted That Met QC Criteria
April 24, 2022
First Posted (ACTUAL)
April 29, 2022
Study Record Updates
Last Update Posted (ACTUAL)
April 29, 2022
Last Update Submitted That Met QC Criteria
April 24, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ET0038-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumor
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
GI Innovation, Inc.RecruitingAdvanced Solid Tumor | Metastatic Solid TumorKorea, Republic of, United States
-
Xenthera, Inc.Not yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
-
Regeneron PharmaceuticalsRecruitingAdvanced Solid Tumor | Metastatic Solid TumorNetherlands
-
Philogen S.p.A.RecruitingAdvanced Solid Tumor | Metastatic Solid TumorItaly, Germany, Switzerland
-
Novartis PharmaceuticalsTerminatedCancer | Solid Tumor | Advanced Solid TumorJapan
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesChina
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesUnited States
Clinical Trials on ET0038
-
Etern BioPharma (Shanghai) Co., LtdNot yet recruitingAdvanced Solid TumorUnited States